AUROPHARMA · Healthcare
Not filed yet. The deadline is 14 Feb 2026.
| Q2 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|
| Revenue | ₹2,730 cr | ₹2,800 cr | ₹3,177 cr |
| YoY | — | — | +16% |
| EBITDA margin | 26.4% | 31.5% | 31.0% |
| Other income, % of PBT | 21% | 24% | 11% |
| Exceptional items | — | — | — |
| Tax rate | 23% | 27% | 25% |
| Net profit | ₹581 cr | ₹737 cr | ₹724 cr |
| YoY | — | — | +24% |
| Core profit YoY | — | — | +45% |
| EPS | ₹10.01 | ₹12.75 | ₹12.58 |
| Flags | · | · | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.